Verastem (VSTM) Financials: History & Chart

Verastem, Inc.(VSTM)

Biotechnology · Needham, MA

$7.75-0.25 (-3.13%)

Delayed quote: Oct 6, 2026, 4:00 PM EDT

About Verastem, Inc.

Verastem, Inc. is an emerging biopharmaceutical company dedicated to the creation and commercialization of innovative therapeutic agents for cancer treatment. A primary asset in its pipeline is VS-6766, a novel dual RAF/MEK inhibitor that operates by a "clamp" mechanism. This unique action effectively blocks the kinase activity of MEK and disrupts RAF's ability to phosphorylate MEK. The company is actively advancing several clinical trials. RAMP 201 is an adaptive, two-part, multicenter, randomized, open-label study designed to assess both the efficacy and safety of VS-6766, administered alone or in combination with defactinib. Defactinib is an oral small molecule inhibitor of focal adhesion kinase (FAK), and this trial targets patients with recurrent low-grade serous ovarian cancer. Simultaneously, Verastem is conducting RAMP 202, a Phase 2 trial focused on evaluating the safety profile of VS-6766 combined with defactinib. This particular study enrolls patients with non-small cell lung cancer (NSCLC) that harbors KRAS and BRAF mutations, specifically after they have undergone treatment with platinum-based regimens and immune checkpoint inhibitors. Verastem has also forged strategic partnerships to support its development efforts. It holds license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacturing rights of products incorporating VS-6766. Additionally, a similar agreement with Pfizer Inc. pertains to the research, development, production, and marketing of Pfizer's FAK inhibitors for various human applications, including therapeutic, diagnostic, and prophylactic uses. Further expanding its collaborations, Verastem has a clinical agreement with Amgen, Inc. to explore the synergistic potential of VS-6766 alongside Amgen's KRAS-G12C inhibitor, LUMAKRAS™, a combination being investigated in the Phase 1/2 RAMP 203 trial. Founded in 2010, Verastem, Inc. maintains its corporate headquarters in Needham, Massachusetts.

Needham, MA

102 employees

www.verastem.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Daniel W. Paterson

View full financials

Financials

SEC Filings

Quarterly Income Statement (USD)

Swipe horizontally to review earlier periods. The line-item column stays pinned.

Quarterly Report	TTM	Quarter ended Jun 2026	Quarter ended Mar 2026	Quarter ended Dec 2025	Quarter ended Sep 2025	Quarter ended Jun 2025	Quarter ended Mar 2025	Quarter ended Dec 2024	Quarter ended Sep 2024
Revenue	87.53M	40.08M	18.67M	17.54M	11.24M	2.14M	0.00	0.00	0.00
Cost of Goods Sold	11.65M	4.04M	3.05M	2.89M	1.67M	446K	0.00	0.00	0.00
Gross Profit	75.87M	36.04M	15.62M	14.64M	9.57M	1.69M	0.00	0.00	0.00
Gross Profit Margin	86.7%	89.9%	83.7%	83.5%	85.1%	79.1%	N/A	N/A	N/A
Total Operating Expenses	235.67M	68.75M	60.52M	56.12M	50.29M	45.45M	44.17M	31.59M	37.03M
Research & Development	140.22M	41.34M	38.22M	31.68M	28.99M	24.79M	29.15M	20.81M	24.75M
Selling, General & Administrative	95.16M	27.41M	22.30M	24.44M	21.01M	20.67M	15.02M	10.78M	12.28M
Operating Income (EBIT)	-159.80M	-32.71M	-44.90M	-41.47M	-40.72M	-43.76M	-44.17M	-31.59M	-37.03M
Operating Margin	-182.6%	-81.6%	-240.5%	-236.5%	-362.2%	-2047.9%	N/A	N/A	N/A
Income Before Tax (EBT)	-201.88M	-33.86M	-36.59M	-32.92M	-98.52M	-25.93M	-52.10M	-64.37M	-23.97M
Interest Income	4.69M	1.11M	1.30M	1.10M	1.18M	822K	960K	968K	831K
Interest Expense	1.48M	360K	382K	415K	319K	212K	192K	1.15M	1.15M
Other Income/Expense	-42.09M	-1.15M	8.31M	8.56M	-57.80M	17.83M	-7.93M	-32.78M	13.06M
Net Income	-202.70M	-34.67M	-36.59M	-32.92M	-98.52M	-25.93M	-52.10M	-64.55M	-23.97M
Income Tax Expense	816K	816K	0.00	0.00	0.00	0.00	0.00	185K	0.00
Net Profit Margin	-231.6%	-86.5%	-196.0%	-187.7%	-876.3%	-1213.6%	N/A	N/A	N/A
EBITDA	-158.65M	-32.43M	-44.62M	-41.18M	-40.42M	-43.64M	-44.16M	-31.58M	-37.02M
EBITDA Margin	-181.3%	-80.9%	-239.0%	-234.8%	-359.6%	-2041.9%	N/A	N/A	N/A
Depreciation & Amortization	1.15M	280K	279K	298K	292K	128K	10K	7K	7K
EPS Basic	-2.46	-0.35	-0.37	-0.39	-1.35	-0.39	-0.96	-1.70	-0.60
EPS Diluted	-2.46	-0.35	-0.37	-0.39	-1.35	-0.32	-0.96	-1.70	-0.60
Weighted Average Basic Shares	100.12M	100.12M	98.29M	83.40M	73.16M	66.14M	54.17M	37.99M	40.26M
Weighted Average Diluted Shares	100.12M	100.12M	99.15M	83.40M	73.16M	74.04M	54.17M	37.99M	40.26M

Annual Income Statement (USD)

Swipe horizontally to review earlier years. The line-item column stays pinned.

Annual Report	12/31/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018
Revenue	30.91M	10.00M	0.00	2.60M	2.05M	88.52M	17.46M	26.72M
Cost of Goods Sold	5.30M	0.00	0.00	0.00	0.00	33.74M	2.81M	588K
Gross Profit	25.62M	10.00M	0.00	2.60M	2.05M	54.77M	14.65M	26.13M
Gross Profit Margin	82.9%	100.0%	N/A	100.0%	100.0%	61.9%	83.9%	97.8%
Total Operating Expenses	195.75M	124.96M	92.08M	75.53M	63.46M	104.13M	146.99M	120.91M
Research & Development	114.60M	81.33M	61.36M	50.56M	39.35M	41.38M	45.78M	43.65M
Selling, General & Administrative	81.15M	43.62M	30.73M	24.98M	24.11M	62.76M	101.21M	77.27M
Operating Income (EBIT)	-170.13M	-114.96M	-92.08M	-72.94M	-61.41M	-49.36M	-132.34M	-94.78M
Operating Margin	-550.3%	-1149.6%	N/A	-2809.6%	-2991.2%	-55.8%	-758.1%	-354.8%
Income Before Tax (EBT)	-209.47M	-130.45M	-87.37M	-73.81M	-71.20M	-67.53M	-149.21M	-72.43M
Interest Income	4.07M	4.15M	6.21M	1.22M	181K	515K	4.38M	2.60M
Interest Expense	1.14M	4.56M	4.14M	2.14M	9.97M	15.79M	20.61M	5.81M
Other Income/Expense	-39.34M	-15.50M	4.72M	-875K	-9.79M	-18.17M	-16.87M	22.35M
Net Income	-209.47M	-130.64M	-87.37M	-73.81M	-71.20M	-67.73M	-149.21M	-72.43M
Income Tax Expense	0.00	185K	0.00	0.00	0.00	194K	0.00	0.00
Net Profit Margin	-677.6%	-1306.4%	N/A	-2843.3%	-3468.1%	-76.5%	-854.8%	-271.1%
EBITDA	-169.40M	-114.93M	-92.02M	-72.82M	-61.34M	-48.10M	-130.16M	-93.36M
EBITDA Margin	-548.0%	-1149.3%	N/A	-2805.0%	-2987.7%	-54.3%	-745.7%	-349.4%
Depreciation & Amortization	728K	26K	62K	118K	72K	1.25M	2.18M	1.42M
EPS Basic	-3.02	-3.66	-3.96	-4.57	-4.92	-5.28	-24.01	-13.44
EPS Diluted	-3.02	-3.66	-3.96	-4.57	-4.92	-5.28	-24.01	N/A
Weighted Average Basic Shares	69.31M	35.71M	22.05M	16.14M	14.53M	12.78M	6.21M	5.78M
Weighted Average Diluted Shares	69.31M	35.71M	22.05M	16.14M	14.53M	12.78M	6.21M	5.78M

Values are displayed in USD. Negative numbers shown in red.

Values are displayed in USD. Negative numbers are shown in red.